Literature DB >> 26323595

A Novel von Hippel Lindau Gene Intronic Variant and Its Reclassification from VUS to Pathogenic: the Impact on a Large Family.

A Sexton1, L Rawlings2, G McKavanagh2, K Simons2, I Winship3.   

Abstract

We present a case where a variant of uncertain significance in the von Hippel Lindau syndrome gene (VHL) was identified in a proband with haemangioblastoma, and in a second degree relative with phaeochromocytoma. Initial uncertainty due to the unclear nature of the variant created psychosocial challenges for this family, in which four other genetic conditions were also present. Subsequent RNA studies confirmed this as a novel pathogenic mutation affecting splicing of exon 2. A third relative has since been diagnosed with haemangioblastoma. We suggest that this mutation possibly has reduced penetrance as there was no history of haemangioblastoma, renal tumours (apart from small cysts) or other VHL tumours among five mutation positive and seven untested adult relatives at 50 % risk of the VHL mutation (average age 46 years, range 18-70 years). This case presents a novel VHL splicing mutation and highlights the psychosocial and medical value of additional laboratory studies on uncertain variants for individuals, their families and for the health professionals providing advice and counseling.

Entities:  

Keywords:  Genetic counseling; Splicing mutation; Uncertainty; VUS; von Hippel Lindau syndrome

Mesh:

Substances:

Year:  2015        PMID: 26323595     DOI: 10.1007/s10897-015-9875-z

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  29 in total

1.  Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Authors:  M E Cockman; N Masson; D R Mole; P Jaakkola; G W Chang; S C Clifford; E R Maher; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

2.  Psychosocial impact of Von Hippel-Lindau disease: levels and sources of distress.

Authors:  C R M Lammens; E M A Bleiker; S Verhoef; F J Hes; M G E M Ausems; D Majoor-Krakauer; R H Sijmons; R B van der Luijt; A M W van den Ouweland; T A M Van Os; N Hoogerbrugge; E B Gómez García; C J Dommering; C M Gundy; N K Aaronson
Journal:  Clin Genet       Date:  2010-02-11       Impact factor: 4.438

3.  The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system.

Authors:  S Gläsker; B U Bender; T W Apel; E Natt; V van Velthoven; R Scheremet; J Zentner; H P Neumann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

4.  Hemangioblastomas of central nervous system: molecular genetic analysis and clinical management.

Authors:  Domenico Catapano; Lucia Anna Muscarella; Vito Guarnieri; Leopoldo Zelante; Vincenzo Antonio D'Angelo; Leonardo D'Agruma
Journal:  Neurosurgery       Date:  2005-06       Impact factor: 4.654

5.  Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.

Authors:  Yves Pastore; Katerina Jedlickova; Yongli Guan; Enli Liu; James Fahner; Henrik Hasle; Jaroslav F Prchal; Josef T Prchal
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

6.  Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas.

Authors:  Cezary Cybulski; Joanna Matyjasik; Marianna Soroka; Janusz Szymaś; Bohdan Górski; Tadeusz Debniak; Anna Jakubowska; Andrzej Bernaczyk; Lech Zimnoch; Grazyna Bierzyńska-Macyszyn; Tomasz Trojanowski; Teresa Wierzba-Bobrowicz; Edmund Prudlak; Alicja Markowska-Wojciechowska; Przemysław Nowacki; Andrzej Roszkiewicz; Radzisław Kordek; Tadeusz Szylberg; Ewa Matyja; Krzysztof Zieliński; Bogdan Woźniewicz; Anna Taraszewska; Wojciech Kozłowski; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2004-03-15       Impact factor: 2.857

7.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.

Authors:  C E Stebbins; W G Kaelin; N P Pavletich
Journal:  Science       Date:  1999-04-16       Impact factor: 47.728

8.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

9.  Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.

Authors:  E R Maher; A R Webster; F M Richards; J S Green; P A Crossey; S J Payne; A T Moore
Journal:  J Med Genet       Date:  1996-04       Impact factor: 6.318

Review 10.  Familial Mediterranean fever--a review.

Authors:  Mordechai Shohat; Gabrielle J Halpern
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

View more
  5 in total

1.  The Expression of VHL (Von Hippel-Lindau) After Traumatic Spinal Cord Injury and Its Role in Neuronal Apoptosis.

Authors:  Jie Hao; Xiaoqing Chen; Ting Fu; Jie Liu; Mingchen Yu; Wei Han; Shuang He; Rong Qian; Feng Zhang
Journal:  Neurochem Res       Date:  2016-06-21       Impact factor: 3.996

2.  Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System.

Authors:  Hélène Tubeuf; Sandrine M Caputo; Teresa Sullivan; Julie Rondeaux; Sophie Krieger; Virginie Caux-Moncoutier; Julie Hauchard; Gaia Castelain; Alice Fiévet; Laëtitia Meulemans; Françoise Révillion; Mélanie Léoné; Nadia Boutry-Kryza; Capucine Delnatte; Marine Guillaud-Bataille; Linda Cleveland; Susan Reid; Eileen Southon; Omar Soukarieh; Aurélie Drouet; Daniela Di Giacomo; Myriam Vezain; Françoise Bonnet-Dorion; Violaine Bourdon; Hélène Larbre; Danièle Muller; Pascal Pujol; Fátima Vaz; Séverine Audebert-Bellanger; Chrystelle Colas; Laurence Venat-Bouvet; Angela R Solano; Dominique Stoppa-Lyonnet; Claude Houdayer; Thierry Frebourg; Pascaline Gaildrat; Shyam K Sharan; Alexandra Martins
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

3.  Patient perspectives on variant reclassification after cancer susceptibility testing.

Authors:  Colin M E Halverson; Laurie M Connors; Bronson C Wessinger; Ellen W Clayton; Georgia L Wiesner
Journal:  Mol Genet Genomic Med       Date:  2020-04-24       Impact factor: 2.183

4.  Rare variant in the fumarate hydratase gene found in patients with clinical features of hereditary leiomyomatosis and renal cell cancer (HLRCC): A case series.

Authors:  Keith Franke; Jennie Vagher; Julie Boyle; April Hall; Kelcy Smith-Simmer
Journal:  Clin Case Rep       Date:  2022-03-01

Review 5.  Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack.

Authors:  João Castro-Teles; Bernardo Sousa-Pinto; Sandra Rebelo; Duarte Pignatelli
Journal:  Endocr Connect       Date:  2021-10-27       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.